Altimmune, Inc. — Director's Dealing 2022

May 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-05-24

Reporting Person: Drutz David (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-24	Common Stock, par value $0.0001	P	1200	$4.50	Acquired	19012	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	333	Indirect

Footnotes

F1: Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.